Last reviewed · How we verify
Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis
Approved treatments
- Afinitor · Novartis
Afinitor works by blocking the mTOR protein, which is involved in cell growth and division. - Afinitor · Central European Society for Anticancer Drug Research
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis patent landscape — cliff calendar, originator estates, attackable patents
- Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis treatment landscape brief
- Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis treatment updates RSS
Frequently asked questions about Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis
What drugs treat Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis?
Tracked treatments include Afinitor.
What is the treatment for Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis?
Standard treatment for Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis includes Afinitor. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis patent cliff · Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis CI report
- Treatment: Afinitor · Novartis
- Treatment: Afinitor · Central European Society for Anticancer Drug Research
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing